Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer
NCT01506609
Completed
The primary objective of the study is to assess the progression-free survival (PFS) of oral veliparib in combination with TMZ or in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in subjects with BRCA1 or BRCA2 mutation and locally recurrent or metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/27/2021
Locations: University of Alabama at Birmingham - Main /ID# 62994, Birmingham, Alabama +119 locations
Conditions: Metastatic Breast Cancer
Register for Updates
Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy
NCT03607955
Withdrawn
The receptor tyrosine kinase AXL is a pathway that plays a crucial role in metastasis and chemoresistance. Overexpression of AXL has been associated with metastasis, recurrence, and chemoresistance in various cancer including ovarian cancer\[16, 17\]}. Targeting AXL is an attractive approach because it is overexpressed among patients with epithelial ovarian cancer and strongly associated with advanced stages, high grade cancer and shorter median survival time. AVB-S6-500 is a potent AXL inhibito... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/23/2021
Locations: Washington University School of Medicine, Saint Louis, Missouri +1 locations
Conditions: Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Register for Updates
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
NCT01454102
Completed
* The study is evaluating the safety and tolerability of Nivolumab (BMS-936558) when combined with three platinum-based doublet chemotherapy regimens (Cisplatin/Gemcitabine; Cisplatin/Pemetrexed; and Carboplatin/Paclitaxel) in subjects with NSCLC. * The study is evaluating the safety and tolerability of Nivolumab as maintenance therapy in combination with Bevacizumab/Avastin that will be given after at least 4 cycles of platinum doublet chemotherapy. * The study is evaluating the safety and tole... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/20/2021
Locations: Ucla, Los Angeles, California +11 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer
NCT02551159
Completed
This is a randomized, open-label, multi-center, 3-arm, global Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination or MEDI4736 monotherapy versus SoC (EXTREME regimen) in the treatment of patients with SCCHN who have not received prior systemic chemotherapy for recurrent or metastatic disease.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
09/16/2021
Locations: Research Site, Aurora, Colorado +196 locations
Conditions: Squamous Cell Carcinoma of the Head and Neck
Register for Updates
Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00025272
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining topotecan, carboplatin, and etoposide in treating patients who have extensive-stage small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
09/07/2021
Locations: Southeastern Medical Oncology Center, Goldsboro, North Carolina +4 locations
Conditions: Lung Cancer
Register for Updates
Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00025285
Completed
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining thalidomide with chemotherapy may kill more tumor cells and be an effective treatment for stage IIIB or stage IV non-small cell lung cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus thalidomide in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
09/07/2021
Locations: CCOP - Central Illinois, Decatur, Illinois +4 locations
Conditions: Lung Cancer
Register for Updates
Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
NCT00028938
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Epoetin alfa may stimulate red blood cell production and prevent or treat anemia in patients who are undergoing radiation therapy and chemotherapy. It is not yet known if chemotherapy combined with radiation therapy is more effective with or without epoetin alfa in treating non-small cell lung cancer. PURPOSE: Ra... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
09/07/2021
Locations: Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina
Conditions: Lung Cancer
Register for Updates
Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
NCT02565901
Terminated
This partially randomized phase I/II trial studies the side effects and how well sirolimus works when given together with docetaxel and carboplatin in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). Biological therapies, such as sirolimus, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as docetaxel... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/03/2021
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7, Metastatic Malignant Neoplasm in the Bone
Register for Updates
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT02366143
Completed
This randomized, open-label study evaluated the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 \[PD-L1\] antibody) in combination with carboplatin+paclitaxel with or without bevacizumab compared with treatment with carboplatin+paclitaxel+bevacizumab in chemotherapy-naïve participants with Stage IV non-squamous NSCLC. Participants were randomized in a 1:1:1 ratio to Arm A (Atezolizumab+Carboplatin+Paclitaxel), Arm B (Atezolizumab+Carboplatin+Paclitaxel+Bevacizum... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2021
Locations: Ironwood Cancer & Research Centers, Chandler, Arizona +239 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT00004202
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as RSR13 may make tumor cells more sensitive to radiation therapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, radiation therapy, and RSR13 in treating patients who have stage III non-small cell lung cancer that cannot be removed by surgery.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/20/2021
Locations: Arizona Cancer Center, Tucson, Arizona +15 locations
Conditions: Lung Cancer
Register for Updates
Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer
NCT03872505
Withdrawn
This phase II randomized trial is for patients with clinical stage II-III, ER and PR \<10%, HER2-negative invasive breast carcinoma (triple negative breast cancer) for whom adjuvant RT is planned and pre-operative RT is deemed feasible by the treating radiation oncologist. Subjects will be randomized into arm A or B and treatment will last for 16 weeks. Both groups will receive Durvalumab 750mg IV Q2 weeks x 2 then a biopsy prior to durvalumab 1500mg IV Q4 weeks x 3 with paclitaxel and carboplat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2021
Locations: Cedars Sinai Medical Center, Los Angeles, California
Conditions: Breast Cancer, Triple Negative Breast Cancer
Register for Updates
Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer
NCT03394885
Completed
The main purpose of this study is to validate a safe dose of atezolizumab with dose-dense paclitaxel and carboplatin when utilized with neoadjuvant chemotherapy and interval cytoreductive surgery followed by maintenance atezolizumab in women with advanced ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/10/2021
Locations: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland +2 locations
Conditions: Ovarian Cancer, Ovarian Neoplasms
Register for Updates